$LSTA Cashflow Statement | Understand Stock

$LSTA

$1.06 +$0.06 (6.44%) Close

$LSTA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2025	FY2023 12 months to Dec 31, 2024	FY2022 12 months to Dec 31, 2023	FY2021 12 months to Dec 31, 2022	FY2020 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense
In process research and development expenses
Gain on disposal of assets
In-process research and development expenses
Share-based compensation expense
Depreciation and amortization
Loss from equity method investment
Loss on disposal of fixed assets
Impairment of non-financial asset
Amortization/accretion on marketable securities
Allowance for credit losses
Changes in operating assets and liabilities:
Accounts receivable
Prepaid and other current assets
Other assets
Accounts payable, accrued liabilities and other liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchase of marketable securities
Sales of marketable securities
Asset acquisition costs, net of cash acquired related to Merger
Investment in Impilo Therapeutics
Purchases of property and equipment
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from exercise of options
Tax withholding payments on net share settlement equity awards
Net proceeds from issuance of common stock
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Interest
Taxes
Issuance of common stock in connection with Merger
Incremental fair value of Cend's fully vested stock options assumed

Comments